![]() |
市場調查報告書
商品編碼
1347346
鼻噴霧劑市場 - 按類型(類固醇、抗組胺藥、減充血劑、鹽水)、按應用(鼻竇炎、過敏性鼻炎、鼻息肉)、按患者(成人、兒童)、按配銷通路(醫院、零售、線上)- 2023 年全球預測到2032年Nasal Spray Market - By Type (Steroid, Antihistamine, Decongestant, Saline), By Application (Sinusitis, Allergic Rhinitis, Nasal Polyps), By Patient (Adult, Pediatric), By Distribution Channel (Hospital, Retail, Online)- Global Forecast 2023 to 2032 |
由於過敏性鼻炎和鼻竇炎的患病率不斷增加,預計鼻噴霧劑市場在 2023 年至 2032 年的預測時間內將出現強勁成長。
隨著環境污染物的增加和生活方式的改變,越來越多的人受到這些呼吸道疾病的困擾,從而增加了對鼻噴霧劑的需求。根據世界過敏組織的數據,全世界有超過 4 億人患有過敏性鼻炎,並且經常被誤診和治療不足。在美國,它影響著 10-30% 的成年人口和高達 40% 的兒童,使其成為第六大流行慢性病。鼻噴霧劑可立即緩解鼻塞和相關症狀,為患者提供方便的解決方案。
此外,製藥公司正在積極開發創新配方,以滿足這種不斷成長的需求,進一步推動市場成長。舉個例子,2023年5月,Bausch Health Companies Inc.宣布推出RYALTRIS(R),這是一種經加拿大衛生部授權的新型處方療法,用於對兒童、青少年中度、輕度至重度季節性過敏性鼻炎及相關症狀進行對症治療和成人。
鼻噴霧劑市場按類型、應用、患者、配銷通路和地區分類。
抗組胺鼻噴霧劑市場佔據了很大的收入佔有率,由於其廣泛用於治療過敏性鼻炎,預計到 2032 年將獲得顯著的成長。這些噴霧劑通過阻斷組胺受體起作用,有效緩解過敏症狀。隨著患者尋求快速且持久的解決方案,製藥公司繼續開發和銷售抗組胺鼻噴霧劑,從而促進了該細分市場的成長。例如,2022 年 6 月,拜耳的 Astepro 過敏鼻噴霧劑獲得 FDA 批准可作為非處方藥使用。它是第一個在美國被批准作為非處方藥用於治療過敏的無類固醇抗組胺鼻噴霧劑。
到2032年底,過敏性鼻炎應用領域的鼻噴霧劑市場佔有率有望積累可觀的收入佔有率。隨著全球過敏性鼻炎發病率的上升,對鼻噴霧劑作為主要治療方式的需求也相應激增。由於鼻噴霧劑在治療過敏性鼻炎方面的便利性和非侵入性,人們對鼻噴霧劑的偏好正在上升,這將對該細分市場的成長產生積極影響。
根據配銷通路,在因各種疾病尋求治療的患者不斷湧入的推動下,醫院領域的鼻噴霧劑市場可能會在2023年至2032年期間以強勁的速度成長。此外,許多鼻噴霧劑都是處方型的,醫院有足夠的設備可以開具處方並將這些產品直接分發給患者。這種固有的能力確保了鼻噴霧劑的可靠和高效的供應鏈,使患者能夠無縫地獲得所需的藥物,從而進一步增加到 2032 年該部門的收入。
由於人們越來越認知到鼻噴霧劑是治療呼吸道疾病的一種方便有效的藥物,亞太地區鼻噴霧劑行業將在 2032 年大幅擴張。此外,亞太地區人口的快速成長,與人口老齡化相一致,增加了通常需要鼻噴霧劑的慢性疾病的患病率。此外,許多亞太國家醫療保健基礎設施的改善、醫療保健資訊的獲取以及可支配收入的增加,使得鼻噴霧劑更容易獲得和負擔得起,從而推動市場成長。
Nasal Spray Market is anticipated to experience robust growth during the forecast timeline from 2023 to 2032 due to the increasing prevalence of allergic rhinitis and sinusitis.
With rising environmental pollutants and changing lifestyles, more individuals are afflicted by these respiratory conditions, driving up demand for nasal sprays. According to the World Allergy Organization, more than 400 million individuals worldwide suffer from allergic rhinitis, which is often misdiagnosed and undertreated. It affects 10-30% of the adult general population and up to 40% of children in the United States, making it the sixth most prevalent chronic condition. Nasal sprays provide instant relief from congestion and related symptoms, offering a convenient solution for sufferers.
Moreover, pharmaceutical companies are actively developing innovative formulations to cater to this growing demand, further propelling the market growth. To cite an instance, in May 2023, Bausch Health Companies Inc. announced the launch of RYALTRIS®, a novel prescription therapy authorized by Health Canada for the symptomatic management of moderate mild to severe seasonal allergic rhinitis and associated symptoms in children, adolescents, and adults.
The nasal spray market is classified by type, application, patient, distribution channel, and region.
The antihistamine nasal spray market accounted for a substantial revenue share and is estimated to gain notable traction through 2032, attributed to their widespread use in the treatment of allergic rhinitis. These sprays work by blocking histamine receptors, alleviating allergy symptoms effectively. As patients seek rapid and long-lasting solutions, pharmaceutical companies continue developing and marketing antihistamine nasal sprays, contributing to the segment growth. For instance, In June 2022, Astepro allergy nasal spray from Bayer received FDA clearance for over-the-counter use. It is the very first steroid-free antihistamine nasal spray for the treatment of allergies to be approved for over-the-counter usage in the USA.
The nasal spray market share from the allergic rhinitis application segment is poised to amass considerable revenue share by the end of 2032. With the rising incidence of allergic rhinitis worldwide, there has been a corresponding surge in demand for nasal sprays as a primary mode of treatment. The preference for nasal sprays is rising due to their convenience and non-invasiveness in the management of allergic rhinitis, which will positively impact the segment growth.
Based on the distribution channel, the nasal spray market from the hospital segment could grow at a robust growth rate from 2023-2032, driven by the constant influx of patients seeking treatment for various medical conditions. Additionally, many nasal sprays are prescription-based, and hospitals are well-equipped to issue prescriptions and dispense these products directly to patients. This inherent capability ensures a reliable and efficient supply chain for nasal sprays, offering patients seamless access to the required medications, further bolstering the segment revenue through 2032.
The Asia Pacific nasal spray industry will expand significantly through 2032, driven by the increasing awareness of nasal sprays as a convenient and effective remedy for respiratory conditions. Additionally, the rapidly growing population in APAC, in line with the aging demographic, has increased the prevalence of chronic ailments that often require nasal sprays. Furthermore, the presence of improved healthcare infrastructure, access to healthcare information, and rising disposable income in many APAC countries have made nasal sprays more accessible and affordable, thereby driving market growth.